ObsEva SA (OBSV)

[Pan_O_War]

Repost: Look at the progression over the last quarter. The Company files for Linzagolix regulatory approval in the EU and US (Sept-2021) respectively following strong phase-III data including longitudinal performance, they hire/appoint a CTO in-part to shepherd Linzagolix (see URL below), should it receive regulatory approval. They then sign an agreement with Syneos Health to broadly commercialize their product, renegotiate the terms of Linzagolix with Kissei, secure additional capital through JGB with warrants convertible at $3.65 strike price. This is all being accomplished ahead of MAA (Q4-2021) and FDA (Q1-2022E) evaluation of the lead product, while the same drug is being studied concurrently (phase-III) to help those suffering from Endometriosis (Ph-III primary endpoint, Q4-2021) and an additional drug (Ebopiprant) is progressing through Phs-2 to address/mitigate pre-term labor.